Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;83(6):1246-1250.
doi: 10.1002/ddr.21961. Epub 2022 Jun 15.

Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs)

Mehdi Valipour  1 , Hamid Irannejad  1 , Saeed Emami  1
Affiliations

Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs)

Mehdi Valipour et al. Drug Dev Res. 2022 Sep.

Abstract

The causative agent of coronavirus disease-2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enters the host cells via an angiotensin-converting enzyme 2 (ACE2)-mediated endocytosis-dependent manner. Because ACE2 is highly expressed in the heart, SARS-CoV-2 can severely infect heart tissue and arteries, causing acute and chronic damage to the cardiovascular system. Therefore, special attention should be paid to finding appropriate agents to protect this vital system during COVID-19 treatment. Papaverine is a unique vasodilator alkaloid that is clinically used in the treatment of vasospasm. Interestingly, this compound has potent and direct effects on a wide range of viruses, and could also prevent viral exploitation mechanisms of the host cell facilities by inhibiting some cellular signaling pathways such as p38 MAPK. This pathway was recently introduced as a promising target for the treatment of COVID-19. Papaverine also has anti-inflammatory effects which is useful in combating the hyper-inflammatory phase of the COVID-19. Unlike some medications that have severe dosage-restrictions in the treatment of COVID-19 due to cardiac side effects, papaverine is recommended for use in many heart disorders. The ability of papaverine to treat COVID-19 has become more promising when the results of some extensive screenings showed the strong ability of this compound to inhibit the cytopathic effects of SARS-CoV-2 with EC50 of 1.1 μM. Having several therapeutic effects along with desired safety profile raises this hypothesis that papaverine could be a promising compound for the suppression of SARS-CoV-2 and prevention of ischemia/vasoconstriction-related complications in COVID-19 disease, especially in patients with underlying cardiovascular diseases (CVDs).

Keywords: COVID-19; Papaverine; SARS-CoV-2; cardiovascular diseases (CVDs); p38 MAPK.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Possible pathogenesis of SARS‐CoV‐2, and multifunctional therapeutic effects of the papaverine against SARS‐CoV‐2 infection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aggarwal, M. , Leser, G. P. , & Lamb, R. A. (2020). Repurposing papaverine as an antiviral agent against influenza viruses and paramyxoviruses. Journal of Virology, 94(6), e01888–01819. - PMC - PubMed
    1. Arabi, Y. M. , Harthi, A. , Hussein, J. , Bouchama, A. , Johani, S. , Hajeer, A. H. , Saeed, B. T. , Wahbi, A. , Saedy, A. , AlDabbagh, T. , Okaili, R. , Sadat, M. , & Balkhy, H. (2015). Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS‐CoV). Infection, 43(4), 495–501. - PMC - PubMed
    1. Byrd, C. M. , & Hruby, D. E. (2006). Viral proteinases: Targets of opportunity. Drug Development Research, 67(6), 501–510.
    1. Chauhan, D. , Mullins, P. , Thuraisingham, S. , & Schofield, P. (1992). Intracoronary papaverine and complete atrioventricular block. BMJ: British Medical Journal, 305(6858), 870. - PMC - PubMed
    1. Dean, A. Q. , Bozza, W. P. , Twomey, J. D. , Luo, S. , Nalli, A. , & Zhang, B. (2021). The fight against COVID‐19: Striking a balance in the renin–angiotensin system. Drug Discovery Today, 26(10), 2214–2220. - PMC - PubMed